This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rhaleb, N.-E. Articles by Carretero, O. A. Search for Related Content PubMed PubMed Citation Articles by Rhaleb, N.-E. Articles by Carretero, O. A.

(Hypertension. 1999;33:329-334.)
© 1999 American Heart Association, Inc.

Scientific Contributions

Effect of ACE Inhibitor on DOCA-Salt– and Aortic Coarctation–Induced Hypertension in Mice

Do Kinin B₂ Receptors Play a Role?

Nour-Eddine Rhaleb; Hongmei Peng; Marcos E. Alfie; Edward G. Shesely; Oscar A. Carretero

From the Hypertension and Vascular Research Division, Henry Ford Hospital, Detroit, Mich.

Correspondence to Nour-Eddine Rhaleb, PhD, Room 7015 Education & Research Building, Henry Ford Hospital, Hypertension and Vascular Research Division, 2799 West Grand Blvd, Detroit, MI 48202-2689. E-mail nrhaleb1{at}hfhs.org

	Abstract

Top Abstract Introduction Methods Results Discussion References

 
Abstract—Kinins have been shown to play an important role in the cardioprotective effect of ACE inhibitors (ACEi) during heart failure and ischemia-reperfusion. However, it is controversial as to whether kinins oppose the hypertensinogenic effect of deoxycorticosterone acetate plus salt (DOCA-salt) or aortic coarctation and whether they mediate both chronic antihypertensive and cardiac antihypertrophic effects of ACEi in hypertension. Using normal 129/SvEvTac mice and mice lacking the bradykinin B₂ receptor gene (B₂-KO), we investigated whether (1) the hypertensinogenic effect of DOCA-salt or aortic coarctation is enhanced in B₂-KO mice and (2) the chronic antihypertensive and antihypertrophic effects of an ACEi (ramipril, 4 mg · kg^-1 · d^-1) are mediated by B₂ receptors in aortic coarctation (6 weeks)– and DOCA-salt (4 weeks)–induced hypertension. Before surgery, there was no difference between 129/SvEvTac and B₂-KO mice in terms of blood pressure and heart weight, suggesting that kinins are not essential to maintaining normal blood pressure. DOCA-salt (volume expansion) or aortic coarctation (renin-dependent) induced similar hypertension and left ventricular hypertrophy (LVH) in 129/SvEvTac and B₂-KO mice, suggesting that kinins do not play an essential role in the development of DOCA-salt– or aortic coarctation–induced hypertension. We found that B₂ receptors mediate only the early (1 week) but not the late phase (4 weeks) of the chronic hypotensive effect of ACEi in DOCA-salt hypertension. On the other hand, chronic ACE inhibition prevented the development of hypertension and LVH in both 129/SvEvTac and B₂-KO mice given DOCA-salt or subjected to aortic coarctation, suggesting that kinins do not participate in the chronic antihypertensive and antihypertrophic effects of ACEi in these 2 models of hypertension. Thus, in mice, kinins acting via B₂ receptors do not participate in (1) maintenance of normal basal blood pressure, (2) establishment and maintenance of hypertension induced by DOCA-salt or aortic coarctation, and (3) chronic antihypertensive and cardiac antihypertrophic effects of ACEi in DOCA-salt and aortic coarctation hypertension.

Key Words: receptors, bradykinin • angiotensin-converting enzyme inhibitors • deoxycorticosterone • coarctation, aortic • blood pressure • gene regulation

	Introduction

Top Abstract Introduction Methods Results Discussion References

 
Kinins are endogenous vasodilators that act as autocrine/paracrine hormones by activating the release of endothelium-derived relaxing factors and prostaglandins.^{1 2} They act mainly via at least 2 distinct types of receptors, B₁ and B₂.³ Most of the known physiological effects of kinins are mediated by B₂ receptors, which belong to a family of 7-transmembrane domains for hormone receptors linked to G proteins. Angiotensin-converting enzyme inhibitors (ACEi) act mainly by (1) abolishing the conversion of angiotensin (Ang) I to Ang II, a potent vasopressor agent, and (2) inhib-iting the breakdown of bradykinin into inactive fragments.^{4 5} Locally produced kinins appear to play an important role in the protective effect of ACEi in myocardial infarction-induced cardiac dysfunction⁶ and preconditioning in a rat model of ischemia-reperfusion.⁷ These protective effects were absent when B₂ receptors were inhibited with a kinin B₂ receptor antagonist (icatibant or Hoe 140). Ischemia preconditioning was also absent in rats deficient in kininogen and mice with the bradykinin B₂ receptor gene disrupted.⁷ B₂ receptor antagonists have also been reported to completely prevent the antihypertensive and antihypertrophic effects of ACE inhibitors in rats subjected to aortic coarctation⁸ ; this finding was not confirmed in our laboratory.⁹ In addition, it has been shown that deoxycorticosterone (DOCA)-salt hypertension is associated with increased activity of the kallikrein-kinin system^{10 11} and suppression of the plasma renin-angiotensin system.¹² In this regard, Majima et al¹³ found that DOCA-salt induced a faster rise in systolic pressure in kinin-deficient rats (Brown Norway Katholiek, BNK) than controls; moreover, BNK given a high-salt diet or chronic infusion of Ang II become hypertensive compared with controls.^{14 15} On the other hand, using a different approach, Madeddu et al^{16 17} reported that chronic blockade of B₂ receptors with icatibant made rats hypertensive when given a high-salt diet or chronically infused with Ang II. Both Majima and Madeddu concluded that kinins prevent the chronic hypertensinogenic effect of DOCA-salt, high salt or Ang II. However, neither of these findings was confirmed in our laboratory, for reasons that are unclear (Rhaleb et al, unpublished data, 1998). To further document the role of kinins in (1) the development and maintenance of hypertension and (2) the antihypertensive and antihypertrophic effect of chronic ACEi, we used mice with the bradykinin B₂ receptor gene disrupted by gene targeting (B₂-KO).¹⁸ We determined whether the absence of B₂ kinin receptors (1) affects basal blood pressure (BP), (2) potentiates the hypertensinogenic effect of DOCA-salt (volume-dependent) or aortic coarctation (renin-dependent) in mice, and (3) whether the antihypertensive and antihypertrophic effects of chronic ACE inhibition are mediated by kinins acting via B₂ receptors in DOCA-salt– or aortic coarctation–induced hypertension.

	Methods

Top Abstract Introduction Methods Results Discussion References

 
Animals
Nine- to 12-week-old male 129/SvEvTac and B₂-KO mice weighing 23 to 26 g were used for these experiments. Homozygous B₂-KO mice were provided by Fred Hess (Merck Laboratories); they were derived from breeding pairs generated by gene targeting. The B₂-KO homozygous (-/-) breeding pairs were derived from an inbred strain on a 129Sv genetic background and routinely genotyped in our laboratory for the disrupted Bdkrb₂ (B₂ receptor) gene. 129/SvEvTac mice were purchased from Taconic Farms (Germantown, NY) and served as controls. Mice were housed in an air-conditioned room with a 12-hour light/dark cycle, received standard mouse chow (Rodent Laboratory Chow, Purina Mills) and drank tap water. This study was approved by the Henry Ford Hospital Care of Experimental Animals Committee.

DOCA-Salt Hypertension
A silicone rubber sheet containing DOCA (Sigma) at a silicone:DOCA ratio of 3:1 was implanted subcutaneously at a dose of 10 mg per 10 g in uninephrectomized mice. Mice receiving DOCA were given a solution of 1% NaCl and 0.2% KCl to drink. Systolic BP (SBP) was measured 3 times a week for 4 weeks. Animals were divided into 3 groups: (1) controls receiving tap water, (2) mice receiving DOCA-salt, and (3) mice receiving DOCA-salt+ramipril (4 mg · kg^-1 · d^-1 in drinking water) (donated by Hoechst, Cincinnati, Ohio). Treatment started immediately after surgery and continued for 4 weeks.

Aortic Coarctation-Induced Hypertension
U-shaped silver clips with a luminal gap fixed at 0.203 mm were used. Mice were anesthetized with pentobarbital (80 mg/kg IP); the aorta was exposed via an abdominal incision and carefully detached from the vena cava between the left and right renal arteries and the clip gently placed around the aorta. The muscle layer was sutured and the skin incision closed. The sham operation included the entire surgical procedure, except that the aorta was not clipped. Animals were divided into 3 groups: (1) sham, (2) mice receiving aortic coarctation, and (3) mice receiving aortic coarctation+ramipril (4 mg · kg^-1 · d^-1 in drinking water). Treatment started immediately after surgery and continued for 6 weeks.

BP and Tissue Weight
SBP and heart rate (HR) were determined using a validated noninvasive computerized tail-cuff system (BP-2000, Visitech Systems).¹⁹ Mice were trained for 1 week and measurements recorded every 2 days thereafter for 4 weeks. Each session included 2 sets of 10 measurements; to include each set of measurements for an individual mouse, the computer had to identify a BP successfully in at least 6 of the 10 trials within the set. We averaged the data for 3 days per week, then expressed them as 1 SBP and 1 HR per week for each mouse. At the end of the study, direct mean arterial pressure (MAP) and HR were measured via the femoral artery for mice given DOCA-salt or the common carotid artery for mice with aortic coarctation. After anesthesia, a modified polyethylene catheter (PE-10 fused to PE-50; Clay-Adams) was passed into the aorta via either the femoral or carotid artery and subcutaneously brought to the back of the neck. Mice were allowed to recover from anesthesia for 24 hours and then placed in a customized plastic restrainer (Falcon 50-mL tubes, Fisher). Arterial cannulas were connected to BP transducers and monitored on a 4-channel recorder (Brush 440, Gould). BP was recorded continuously in restrained and awake mice in a quiet environment for 30 minutes at 30-sec intervals. After determining BP, mice were anesthetized with 50 mg/kg pentobarbital sodium; the heart was excised, cleaned of blood with saline, and gently blotted to dryness, and left ventricular weight including the septum (LVW), right ventricular (RVW), atrial (AW), and kidney weight (KW) were determined and normalized to 10 g body wt.

Determination of Plasma Renin Concentration in DOCA Groups
Before and 4 weeks after starting DOCA, blood (30 µL) was collected in a preheparinized pipette from ether-anesthetized mice by puncturing the retro-orbital plexus. Plasma renin concentration (PRC) was determined using a method previously described by Harding et al.²⁰ Briefly, plasma (2 µL) was incubated in medium containing a peptidase inhibitor cocktail (3% PMSF in methanol and 3.8% EDTA, pH 6.5) and 250 ng sheep angiotensinogen (expressed in terms of capacity to release Ang I) at 37°C for 30 minutes in a final volume of 200 µL. To terminate the reaction, samples were boiled for 15 minutes and centrifuged at 1680g for 10 minutes and the supernatants were removed. Generated Ang I was measured by a radioimmunoassay using previously published methods,²¹ and the results were expressed as ng Ang I per mL of plasma per hour. Experiments designed to test the validity of this assay have demonstrated that <1% of the substrate is consumed under these conditions and have shown linearity of product generated with time. Nephrectomized sheep angiotensinogen was used as a substrate, since it is known that mouse renin can release Ang I from this heterologous substrate.²²

Statistics
All data were expressed as mean±SEM. For DOCA-salt hypertension, ANOVA with an interaction effect and Student's 2-sample t test were used to evaluate differences between 129/SvEvTac and B₂-KO mice. Paired t tests were performed to look at the early hypotensive effect of ACEi. An adjusted level of 0.01 was used to determine statistical significance due to multiple comparisons. For aortic coarctation-induced hypertension, all data were analyzed using ANOVA. Groups were compared with the control using Dunnett's test; this adjusts the P value from multiple testing while using a pooled estimate of variance. In this case, the familywise P value for testing was 0.05.

	Results

Top Abstract Introduction Methods Results Discussion References

 
DOCA-Salt Hypertension
Basal systolic pressure (SBP) was 109±2 mm Hg (n=20) in 129/SvEvTac mice and 113±3 mm Hg (n=18) in B₂-KOs; SBP tended to be higher in B₂-KO mice, but the difference was not significant (Figure 1). Four weeks after treatment with DOCA-salt, SBP was significantly higher in 129/SvEvTac mice given DOCA-salt (139±3 mm Hg; n=27) than controls (123±3; n=19) (P<0.001); similarly, SBP was significantly higher in DOCA-salt–treated B₂-KO mice (144±2 mm Hg; n=27) than controls (117±5; n=15) (P<0.001) (Figure 1). SBP tended to be greater in B₂-KO mice given DOCA-salt compared with 129/SvEvTac; at week 4, SBP increased by 27 mm Hg in B₂-KO mice and 16 mm Hg in 129/SvEvTac, but the difference was not significant (P=0.07). However, at the end of the study, MAP was similar in both DOCA-salt–treated 129/SvEvTac [153±6 mm Hg; (n=14)] and B₂-KO mice [150±4 mm Hg; (n=13)], and was higher than the respective controls [125±6 (n=11) and 124±4 mm Hg (n=12); P<0.005] (Table 1).

View larger version (25K): [in this window] [in a new window]   Figure 1. Time-dependent increase in tail-cuff SBP in uninephrectomized male 129/SvEvTac and B2-KO mice given DOCA plus 1% NaCl and 0.2% KCl (DOCA-salt). Basal SBP was similar in both strains. At week 4, DOCA-salt induced similar increased SBP in both strains. SBP increased slightly faster in B2-KO mice than in 129/SvEvTac, but the difference was not significant. *P<0.05 and **P<0.005 versus baseline.

View this table: [in this window] [in a new window]   Table 1. Effect of ACEi on Body Weight, AW, RVW, and Total Heart Weight in 129/SvEvTac and B2-KO Mice Given DOCA-Salt

During the first 3 weeks, the ACEi ramipril (4 mg · kg^-1 · d^-1) prevented hypertension in DOCA-salt B₂-KO but only partially in 129/SvEvTac mice (Figure 2). However, at 4 weeks SBP was significantly lower in both strains given DOCA-salt plus ACEi than DOCA-salt alone but similar to controls (P<0.001) (Figure 2). In addition, an early hypotensive effect of ACEi was observed at 1 week in 129/SvEvTac (from 112±2 to 96±5 mm Hg; P<0.005) but was absent in B₂-KO mice (114±2 versus 113±4 mm Hg). At the end of the study, ACEi significantly prevented hypertension in DOCA-salt–treated 129/SvEvTac mice with a MAP of 126±4 mm Hg (n=14) and B₂-KOs with 126±5 mm Hg (n=8); these values were not different from controls but were significantly lower than those measured in mice given DOCA-salt alone (P<0.005) (Table 1). Heart rate was similar in all groups. There was no significant difference between 129/SvEvTac and B₂-KO mice in terms of AW, LVW, RVW, or KW either under control conditions or during DOCA-salt administration; LVW was significantly higher in DOCA-salt mice versus their respective controls in 129/SvEvTac [44.1±2 mg per 10 g (n=22) versus 34.5±1.2 (n=16)] and B₂-KO mice [43.6±1.3 mg per 10 g (n=28) versus 36.4±1.2 (n=16); P<0.001] (Table 1). DOCA-salt hypertension was also associated with significantly increased AW and RKW compared with the respective controls, reaching similar values in both 129/SvEvTac and B₂-KO mice (Table 1). ACE inhibition resulted in reduced AW and LVW in 129/SvEvTac and B₂-KO, becoming similar to the respective controls (Table 1). Unexpectedly, chronic DOCA-salt only attenuated but did not suppress plasma renin concentration (PRC) in 129/SvEvTac [from 1323±489 to 297±72 ng · mL^-1 · h^-1 Ang I (n=8 to 10); P=0.055] and B₂-KO mice [from 620±78 to 369±83 ng · mL^-1 · h^-1 Ang I (n=9); P<0.05] (Figure 3). There was no difference between 129/SvEvTac and B₂-KO mice either before or after DOCA-salt treatment.

View larger version (20K): [in this window] [in a new window]   Figure 2. Effect of ACEi (ramipril, 4 mg · kg-1 · d-1) on DOCA-salt hypertension in 129/SvEvTac (upper panel) and B2-KO mice (lower panel) given DOCA-salt. At week 1, the acute hypotensive effect of ACEi was absent in B2-KO mice. At week 4, SBP was significantly lower in both strains given DOCA-salt plus ACEi than DOCA-salt alone. *P<0.05 and **P<0.005 versus DOCA-salt+ ACEi.

View larger version (25K): [in this window] [in a new window]   Figure 3. Bar graph shows PRC measured in ether-anesthetized male 129/SvEvTac and B2-KO mice given DOCA plus 1% NaCl for 4 weeks. PRC was measured before and after uninephrectomy and DOCA-salt administration. PRC was not totally suppressed, but was significantly attenuated compared with controls. The number of observations is indicated inside the bar corresponding to each group.

Aortic Coarctation-Induced Hypertension
Aortic coarctation for 6 weeks induced hypertension in both 129/SvEvTac and B₂-KO mice. MAP increased to a similar extent in both strains, becoming higher than the sham group [167±4 (n=8) versus 138±3 mm Hg (n=9); P<0.05] for 129/SvEvTac mice and [169±8 (n=7) versus 131±4 mm Hg (n=8); P<0.05] for B₂-KO mice, while heart rate was the same in all 3 groups (Table 2). Aortic coarctation-induced hypertension was associated with greater LVW compared with the respective controls in both 129/SvEvTac mice [42.5±1.0 mg per 10 g BW (n=31) versus 34.3±0.5 (n=29); P<0.001] and B₂-KO mice [48.0±4.1 mg per 10 g (n=13) versus 34.1±1.1 (n=13); P<0.005] (Table 2). Although the difference did not reach significance, we found that hypertensive B₂-KO mice had greater LVW than 129/SvEvTac mice (P=0.21). Chronic treatment with ACEi prevented hypertension similarly in both 129/SvEvTac and B₂-KO, leading to MAP values of 131±12 (n=7) and 123±11 (n=8) mm Hg, respectively (P<0.05). ACEi also prevented left ventricular hypertrophy, leading to a LVW of 33.3±1 mg per 10 g (n=10) for 129/SvEvTac mice given DOCA-salt and ACEi and 30.2±1.2 mg per 10 g (n=11) for B₂-KO (P<0.05). No significant changes were observed for body weight, AW, or RVW due to hypertension in either strain.

View this table: [in this window] [in a new window]   Table 2. Effect of ACEi on Blood Pressure, BW, AW, RVW, and THW in 129/SvEvTac and B2-KO Mice Subjected to Aortic Coarctation

	Discussion

Top Abstract Introduction Methods Results Discussion References

 
These results indicate that basal BP and LVW are no different in wild-type mice (129/SvEvTac) versus mice lacking B₂ receptors (B₂-KO), confirming the findings of Alfie et al²³ but not those of Madeddu et al.²⁴ Madeddu et al found that B₂-KO mice had higher BP and greater LVW compared with 129 Sv/J mice. While we could not explain these conflicting results, we may attribute the differences to the genetic background of the controls. Indeed, we chose 129/SvEvTac mice as our controls because they are genetically closer to B₂-KO mice than the 129Sv/J used by Madeddu et al.²⁴ We based our decision on a recent study examining simple sequence-linked polymorphisms among various mouse 129 substrains.²⁵ This study showed that there were fewer differences between 129/SvEvTac and either of the 2-129 substrains (ES cell line AB 2.1 from J129/Sv and J129/SvEv) previously used by Borkowski et al¹⁸ comprising the B₂-KO mouse genetic background than is the case for 129Sv/J.

The systematic observation of higher MAP values compared with SBP could result from 2 possibilities: (1) mice were trained for 1 week before SBP was measured and thereafter every 2 days for 4 weeks, whereas MAP was measured only 24 hours after the mouse recovered from anesthesia; therefore mice would be under less stress during SBP measurements; and (2) SBP was measured in mice placed on a continuously heated plate (38°C), which may cause dilatation and decreased BP, while MAP was measured in mice placed in a restrainer at room temperature.

DOCA-salt or aortic coarctation induced hypertension and increased LVW in a similar manner in 129/SvEvTac and B₂-KO mice, suggesting that kinins do not play a role in the establishment and maintenance of high BP and left ventricular hypertrophy in these hypertension models. This finding is not compatible with results of Majima et al¹³ and Madeddu et al,¹⁶ who found an exaggerated BP response to DOCA-salt in kinin-deficient rats (BNK) or normal rats that were chronically treated with a B₂ receptor antagonist.

Surprisingly, PRC was only partially reduced in 129/SvEvTac and B₂-KO mice when given DOCA-salt compared with their respective baselines. The remaining PRC in DOCA-salt mice could be due to the existence of 2 genes expressing renin in 129/SvEvTac and B₂-KO mice, namely Ren-1, which expresses renin in the juxtaglomerular apparatus of the kidney, and Ren-2, which expresses renin mainly in the convoluted tubular cells of the submaxillary gland and at very low levels in the kidney.^{26 27} However, it is unclear how the expression of renin from Ren-2 would be affected by DOCA-salt in 129/SvEvTac and B₂-KO mice. Conversely, PRC was suppressed by approximately 90% in mice with 1 renin gene (Ren-1, Balb/c) given DOCA-salt²⁸ ; this is in accord with the 82% PRC suppression and undetectable plasma renin activity observed in rats (1 renin gene) given DOCA-salt.^{29 30} Nevertheless, the remaining high PRC may explain why ACE prevented hypertension and LVW in DOCA-salt mice of both strains, suggesting that the renin-angiotensin system may still be functional during DOCA-salt administration; other mechanisms may also account for the chronic effect of ACEi, such as peptides that are also catabolized by ACE, including substance P,³¹ vasoactive intestinal peptide, met-enkephalin,³² and acetyl-Ser-Asp-Lys-Pro-COOH (Ac-SDKP).³³

Moreover, we found that B₂ receptors mediate only the early but not the late phase of the chronic hypotensive effect of ACEi. This finding is compatible with previous results showing that administration of the ACEi ramipril over 1 week³⁴ or captopril over 60 minutes³⁵ gradually lowered BP in DOCA-salt hypertensive rats and that this effect was completely prevented by a concomitant B₂ kinin receptor antagonist (icatibant).

Our study also showed that chronic ACEi in mice subjected to aortic coarctation completely blunted hypertension and increased LVW in both 129/SvEvTac and B₂-KO strains, suggesting that kinins do not mediate the chronic antihypertensive and antihypertrophic effect of ACEi in this model of hypertension. This last finding confirmed our previous results in rats, showing that a B₂ receptor antagonist (icatibant) did not block the chronic antihypertensive and antihypertrophic effects of ACEi in aortic coarctation-induced hypertension.⁹ In contrast, Linz and Schölkens⁸ reported that icatibant completely blunted the antihypertensive and antihypertrophic effects of ACEi. We cannot explain these discrepancies. Nevertheless, our study suggests that chronic decreased BP and LVW induced by ACEi are unlikely to be due to rising circulating and tissue kinin concentrations but could be attributed to blockade of the conversion of angiotensin I to II, as has been demonstrated in other models, such as the spontaneous hypertension³⁶ and 2K-1C hypertension models.³⁷

In conclusion, we have shown that in mice kinins acting via B₂ receptors (1) do not participate in the maintenance of normal basal BP, (2) are not involved in the development of either DOCA-salt or aortic coarctation hypertension, and (3) are not essential for the chronic antihypertensive and cardiac antihypertrophic effect of ACEi in DOCA-salt and aortic coarctation hypertension.

	Acknowledgments

 
This study was supported by NIH grant HL-28982 and AHA Michigan Affiliate Grant 29GS9789.

Received September 18, 1998; first decision October 16, 1998; accepted November 11, 1998.

	References

Top Abstract Introduction Methods Results Discussion References

 
1. Vanhoutte PM. Endothelium and control of vascular function: state of the art lecture. Hypertension. 1989;13:658–667.[Abstract/Free Full Text]

2. Carretero OA, Scicli AG. The kallikrein-kinin system as a regulator of cardiovascular and renal function. In: Laragh JH, Brenner BM. Hypertension: Physiology, Diagnosis, and Management. New York, NY: Raven Press; 1995:983–999.

3. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev. 1980;32:1–46.[Medline] [Order article via Infotrieve]

4. Erdös EG. Angiotensin I converting enzyme. Circ Res. 1975;36:247–255.[Free Full Text]

5. Campbell DJ, Kladis A, Duncan AM. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. Hypertension. 1994;23:439–449.[Abstract/Free Full Text]

6. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest. 1997;99:1926–1935.[Medline] [Order article via Infotrieve]

7. Yang XP, Liu YH, Scicli GM, Webb CR, Carretero OA. Role of kinins in the cardioprotective effect of preconditioning: study of myocardial ischemia/reperfusion injury in B₂ kinin receptor knockout mice and kininogen-deficient rats. Hypertension. 1997;30:735–740.[Abstract/Free Full Text]

8. Linz W, Schölkens BA. A specific B₂-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol. 1992;105:771–772.[Medline] [Order article via Infotrieve]

9. Rhaleb NE, Yang XP, Scicli AG, Carretero OA. Role of kinins and nitric oxide in the antihypertensive effect of ramipril. Hypertension. 1994;23:865–868.[Abstract/Free Full Text]

10. Geller RG, Margolius HS, Pisano JJ, Keiser HR. Effects of mineralocorticoids, altered sodium intake, and adrenalectomy on urinary kallikrein in rats. Circ Res. 1972;48:728–733.[Free Full Text]

11. Margolius HS, Chao J, Kaizu T. The effects of aldosterone and spironolactone on renal kallikrein in the rat. Clin Sci. 1976;51:279s–282s.

12. Keeton TK, Campbell WB. The pharmacological alteration of renin release. Pharmacol Rev. 1981;31:81–215.

13. Majima M, Katori M, Hanazuka M, Mizogami S, Nakano T, Nakao Y, Mikami R, Uryu H, Okamura R, Mohsin SSJ, Oh-ishi S. Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system. Hypertension. 1991;17:806–813.[Abstract/Free Full Text]

14. Majima M, Yoshida O, Mihara H, Muto T, Mizogami S, Kuribayashi Y, Katori M, Oh-ishi S. High sensitivity to salt in kininogen-deficient Brown Norway Katholiek rats. Hypertension. 1993;22:705–714.[Abstract/Free Full Text]

15. Majima M, Mizogami S, Kuribayashi Y, Katori M, Oh-ishi S. Hypertension induced by a nonpressor dose of angiotensin II in kininogen-deficient rats. Hypertension. 1994;24:111–119.[Abstract/Free Full Text]

16. Madeddu P, Parpaglia PP, Demontis MP, Varoni MV, Fattaccio MC, Tonolo G, Troffa C, Glorioso N. Bradykinin B₂-receptor blockade facilitates deoxycorticosterone-salt hypertension. Hypertension. 1993;21:980–984.[Abstract/Free Full Text]

17. Madeddu P, Parpaglia PP, Demontis MP, Varoni MV, Fattaccio MC, Glorioso N. Chronic inhibition of bradykinin B₂-receptors enhances the slow vasopressor response to angiotensin II. Hypertension. 1994;23:646–652.[Abstract/Free Full Text]

18. Borkowski JA, Ransom RW, Seabrook GR, Trumbauer M, Chen H, Hill RG, Strader CD, Hess JF. Targeted disruption of a B₂ bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem. 1995;270:13706–13710.[Abstract/Free Full Text]

19. Krege JH, Hodgin JB, Hagaman JR, Smithies O. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. Hypertension. 1995;25:1111–1115.[Abstract/Free Full Text]

20. Harding P, Sigmon DH, Alfie ME, Huang PL, Fishman MC, Beierwaltes WH, Carretero OA. Cyclooxygenase-2 mediates increased renal renin content induced by low-sodium diet. Hypertension. 1997;29:297–302.[Abstract/Free Full Text]

21. Haber E, Koerber T, Page CB, Kilman B, Pernode A. Application of a radioimmunoassay for angiotensin I to the physiological measurement of plasma renin activity in normal subjects. J Clin Endocrinol Metabol. 1969;20:1349–1355.

22. Oliver WJ, Gross F. Unique specificity of mouse angiotensinogen to homologous renin. Proc Soc Exp Biol Med. 1966;122:923–926.[Medline] [Order article via Infotrieve]

23. Alfie ME, Yang XP, Hess F, Carretero OA. Salt-sensitive hypertension in bradykinin B₂ receptor knockout mice. Biochem Biophys Res Commun. 1996;224:625–630.[Medline] [Order article via Infotrieve]

24. Madeddu P, Varoni MV, Palomba D, Emanueli C, Demontis MP, Glorioso N, Fulgheri PD, Sarzani R, Anania V. Cardiovascular phenotype of a mouse strain with disruption of bradykinin B₂-receptor gene. Circulation. 1997;96:3570–3578.[Abstract/Free Full Text]

25. Simpson EM, Linder CC, Sargent EE, Davisson MT, Mobraaten LE, Sharp JJ. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nat Genet. 1997;16:19–27.[Medline] [Order article via Infotrieve]

26. Sharp MGF, Fettes D, Brooker G, Clark AF, Peters J, Fleming S, Mullins JJ. Targeted inactivation of the Ren-2 gene in mice. Hypertension. 1996;28:1126–1131.[Abstract/Free Full Text]

27. Kihara M, Umemura S, Sugaya T, Toya Y, Yabana M, Kobayashi S, Tamura K, Kadota T, Kishida R, Murakami K, Fukamizu A, Ishi M. Expression of neuronal type nitric oxide synthase and renin in the juxtaglomerular apparatus of angiotensin type-1a receptor gene-knockout mice. Kidney Int. 1998;53:1585–1593.[Medline] [Order article via Infotrieve]

28. Barrett G, Morgan T, Smith M, Aldred P. Effect of mineralocorticoids and salt loading on renin release, renal renin content and renal renin mRNA in mice. Clin Exp Pharmacol Physiol. 1989;16:631–639.[Medline] [Order article via Infotrieve]

29. Kim S, Ohta K, Hamagushi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, Iwao H. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension. 1994;24:195–204.[Abstract/Free Full Text]

30. Gavras H, Brunner HR, Laragh JH, Vaughan ED Jr, Kross M, Cote LJ, Gavras I. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess: role of renin and sodium in vascular changes. Circ Res. 1975;36:300–309.[Abstract/Free Full Text]

31. Regoli D, Boudon A, Fauchére JC. Receptors and antagonists for substance P and related peptides. Am Soc Exp Ther. 1994;46:551–599.

32. Duggan KA, Ye VZ. Angiotensin-converting enzyme inhibition with enalapril increases the cardiac concentration of vasoactive intestinal peptide. Ann N Y Acad Sci. 1996;805:713–716.[Medline] [Order article via Infotrieve]

33. Azizi M, Rousseau A, Ezan E, Guyene TT, Michelet S, Grognet JM, Lenfant M, Corvol P, Menard J. Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. J Clin Invest. 1996;97:839–844.[Medline] [Order article via Infotrieve]

34. Carretero OA. High-mineralocorticoid conditions: kinins (paracrine hormones) in the regulation of renal function and blood pressure. In: Mornex R, Jaffiol C, Leclere J, eds. Progress in Endocrinology: Proceedings of the Ninth International Congress of Endocrinology, Nice, 1992. London, UK: Parthenon; 1993:536–540.

35. Chen K, Zhang X, Dunham EW, Zimmerman BG. Kinin-mediated antihypertensive effect of captopril in deoxycorticosterone acetate-salt hypertension. Hypertension. 1996;27:85–89.[Abstract/Free Full Text]

36. Nagano M, Higaki J, Mikami H, Nakamura M, Higashimori K, Katahira K, Tabuchi Y, Moriguchi A, Najamura F, Ogihara T. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens. 1991;9:595–599.[Medline] [Order article via Infotrieve]

37. Wilcox CS, Carozo J, Welch WJ. AT₁ and TxA₂/PGH₂ receptors maintain hypertension throughout 2K,1C Goldblatt hypertension in the rat. Am J Physiol. 1996;271:R891–R896.[Abstract/Free Full Text]

This article has been cited by other articles:

				L. C. Sturgis, J. G. Cannon, D. A. Schreihofer, and M. W. Brands The role of aldosterone in mediating the dependence of angiotensin hypertension on IL-6 Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2009; 297(6): R1742 - R1748. [Abstract] [Full Text] [PDF]

				P. Muller, A. Kazakov, P. Jagoda, A. Semenov, M. Bohm, and U. Laufs ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload Cardiovasc Res, July 1, 2009; 83(1): 106 - 114. [Abstract] [Full Text] [PDF]

				C. Cayla, M. Todiras, R. Iliescu, V. V. Saul, V. Gross, B. Pilz, G. Chai, V. F. Merino, J. B. Pesquero, O. C. Baltatu, et al. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension FASEB J, June 1, 2007; 21(8): 1689 - 1698. [Abstract] [Full Text] [PDF]

				C. J. Barrick, M. Rojas, R. Schoonhoven, S. S. Smyth, and D. W. Threadgill Cardiac response to pressure overload in 129S1/SvImJ and C57BL/6J mice: temporal- and background-dependent development of concentric left ventricular hypertrophy Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2119 - H2130. [Abstract] [Full Text] [PDF]

				Y. Sun, O. A. Carretero, J. Xu, N.-E. Rhaleb, F. Wang, C. Lin, J. J. Yang, P. J. Pagano, and X.-P. Yang Lack of Inducible NO Synthase Reduces Oxidative Stress and Enhances Cardiac Response to Isoproterenol in Mice With Deoxycorticosterone Acetate-Salt Hypertension Hypertension, December 1, 2005; 46(6): 1355 - 1361. [Abstract] [Full Text] [PDF]

				L. J. Murphey, W. K. Eccles, G. H. Williams, and N. J. Brown Loss of Sodium Modulation of Plasma Kinins in Human Hypertension J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 1046 - 1052. [Abstract] [Full Text] [PDF]

				A. Hartner, N. Cordasic, B. Klanke, R. Veelken, and K. F. Hilgers Strain differences in the development of hypertension and glomerular lesions induced by deoxycorticosterone acetate salt in mice Nephrol. Dial. Transplant., October 1, 2003; 18(10): 1999 - 2004. [Abstract] [Full Text] [PDF]

				J. Varagic, D. Susic, M. Slama, and E. D. Frohlich Omapatrilat Induces Profound Renal Vasodilation but Does Not Affect Coronary Hemodynamics Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2003; 8(2): 167 - 174. [Abstract] [PDF]

				F. Trabold, S. Pons, A. A. Hagege, M. Bloch-Faure, F. Alhenc-Gelas, J.-F. Giudicelli, C. Richer-Giudicelli, and P. Meneton Cardiovascular Phenotypes of Kinin B2 Receptor- and Tissue Kallikrein-Deficient Mice Hypertension, July 1, 2002; 40(1): 90 - 95. [Abstract] [Full Text] [PDF]

				Q. Wang, E. Hummler, J. Nussberger, S. Clement, G. Gabbiani, H. R. Brunner, and M. Burnier Blood Pressure, Cardiac, and Renal Responses to Salt and Deoxycorticosterone Acetate in Mice: Role of Renin Genes J. Am. Soc. Nephrol., June 1, 2002; 13(6): 1509 - 1516. [Abstract] [Full Text] [PDF]

				I. Duka, S. Shenouda, C. Johns, E. Kintsurashvili, I. Gavras, and H. Gavras Role of the B2 Receptor of Bradykinin in Insulin Sensitivity Hypertension, December 1, 2001; 38(6): 1355 - 1360. [Abstract] [Full Text] [PDF]

				M. Majima, M. Katori, N.-E. Rhaleb, X.-P. Yang, M. Nanba, E. G. Shesely, O. A. Carretero, P. Madeddu, N.-E. Rhaleb, X.-P. Yang, et al. Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats * Response * Role of Kinins in Blood Pressure Regulation: Reality or Fiction * Response Hypertension, October 1, 2001; 38 (4): e21 - e23. [Full Text] [PDF]

				H. Peng, O. A. Carretero, M. E. Alfie, J. A. Masura, and N.-E. Rhaleb Effects of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Type 1 Receptor Antagonist in Deoxycorticosterone Acetate-Salt Hypertensive Mice Lacking Ren-2 Gene Hypertension, March 1, 2001; 37(3): 974 - 980. [Abstract] [Full Text] [PDF]

				I. Duka, E. Kintsurashvili, I. Gavras, C. Johns, M. Bresnahan, and H. Gavras Vasoactive Potential of the B1 Bradykinin Receptor in Normotension and Hypertension Circ. Res., February 16, 2001; 88(3): 275 - 281. [Abstract] [Full Text] [PDF]

				N.-E. Rhaleb, X.-P. Yang, M. Nanba, E. G. Shesely, and O. A. Carretero Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats Hypertension, January 1, 2001; 37(1): 121 - 128. [Abstract] [Full Text] [PDF]

				P. Madeddu, C. Emanueli, N.-E. Rhaleb, E. G. Shesely, and O. A. Carretero Can Knockout Mice Help Dissect Relevant Genes in Hypertension? Evidence and Confounding Factors • Response Hypertension, December 1, 1999; 34 (6): e14 - e15. [Full Text] [PDF]

				V. Gaussin and M. D. Schneider Surviving Infarction One Gene at a Time : Decreased Remodeling and Mortality in Engineered Mice Lacking the Angiotensin II Type 1A Receptor Circulation, November 16, 1999; 100(20): 2043 - 2044. [Full Text] [PDF]

				X.-P. Yang, Y.-H. Liu, N.-E. Rhaleb, N. Kurihara, H. E. Kim, and O. A. Carretero Echocardiographic assessment of cardiac function in conscious and anesthetized mice Am J Physiol Heart Circ Physiol, November 1, 1999; 277(5): H1967 - H1974. [Abstract] [Full Text] [PDF]

				X.-P. Yang, Y.-H. Liu, D. Mehta, M. A. Cavasin, E. Shesely, J. Xu, F. Liu, and O. A. Carretero Diminished Cardioprotective Response to Inhibition of Angiotensin-Converting Enzyme and Angiotensin II Type 1 Receptor in B2 Kinin Receptor Gene Knockout Mice Circ. Res., May 25, 2001; 88(10): 1072 - 1079. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rhaleb, N.-E. Articles by Carretero, O. A. Search for Related Content PubMed PubMed Citation Articles by Rhaleb, N.-E. Articles by Carretero, O. A.